By Abigail Townsend
Date: Thursday 23 Jul 2026
(Sharecast News) - A breast cancer drug developed by AstraZeneca has been approved in the European Union for the treatment of certain types of the disease, the pharmaceutical giant announced on Thursday.
Used in combination with a CDK4/6 inhibitor, Etcamah has been approved by Brussels for the treatment of adults with...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news